| Item |
Information |
|
Drug Groups
|
approved; investigational |
|
Description
|
Vapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer. |
| Indication |
For the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea. |
| Pharmacology |
Vapreotide is a somatostatin analog with a higher metabolic stability than the parent hormone. Vapreotide reduces splanchnic blood flow; inhibits growth hormone release, and inhibits the release of peptides and vasoactive compounds from neuroendocrine tumors. |
| Toxicity |
Safety data are limited, however, headache, fatigue, diarrhea, nausea, vomiting, and abdominal pain have been reported commonly with the use of vapreotide. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Half Life |
30 minutes |
| Elimination |
Vapreotide is 76% eliminated in bile. The remainder is renally eliminated. |
| References |
| • |
Sarr MG: The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. J Am Coll Surg. 2003 Apr;196(4):556-64; discussion 564-5; author reply 565.
[Pubmed]
|
| • |
Vapreotide: BMY 41606, RC 160, Sanvar. Drugs R D. 2003;4(5):326-30.
[Pubmed]
|
| • |
Norman P: Vapreotide (Debipharm). IDrugs. 2000 Nov;3(11):1358-72.
[Pubmed]
|
| • |
Betoin F, Ardid D, Herbet A, Aumaitre O, Kemeny JL, Duchene-Marullaz P, Lavarenne J, Eschalier A: Evidence for a central long-lasting antinociceptive effect of vapreotide, an analog of somatostatin, involving an opioidergic mechanism. J Pharmacol Exp Ther. 1994 Apr;269(1):7-14.
[Pubmed]
|
| • |
Girard PM, Goldschmidt E, Vittecoq D, Massip P, Gastiaburu J, Meyohas MC, Coulaud JP, Schally AV: Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases. AIDS. 1992 Jul;6(7):715-8.
[Pubmed]
|
| • |
Stiefel F, Morant R: Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer. Support Care Cancer. 1993 Jan;1(1):57-8.
[Pubmed]
|
| • |
Betoin F, Eschalier A, Duchene-Marullaz P, Lavarenne J: Seven-day antinociceptive effect of a sustained release vapreotide formulation. Neuroreport. 1994 Jan 31;5(5):642-4.
[Pubmed]
|
|
|